XML 15 R46.htm IDEA: XBRL DOCUMENT v3.3.0.814
Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Oct. 31, 2015
Oct. 31, 2015
Oct. 31, 2014
Revenues:      
Clinical laboratory services   $ 17,090 $ 15,822
Product revenues   7,687 8,002
Royalty and license fee income   400 1,000
Total revenues   25,177 24,824
Operating expenses:      
Cost of clinical laboratory services   10,332 10,130
Cost of product revenues   3,611 3,695
Research and development   867 791
Selling, general and administrative   10,225 10,285
Provision for uncollectible accounts receivable   704 541
Legal fee expense   1,601 2,466
Legal settlement, net $ (170) (6,800)  
Operating income (loss)   4,637 (3,084)
Other income (expense)      
Other   54 19
Foreign exchange gain (loss)   (130) (472)
Share-based compensation included in above:      
Share-based compensation   111 98
Clinical Labs [Member]      
Revenues:      
Clinical laboratory services   17,090 15,822
Total revenues   17,090 15,822
Operating expenses:      
Cost of clinical laboratory services   10,332 10,130
Selling, general and administrative   5,286 5,066
Provision for uncollectible accounts receivable   708 530
Legal fee expense   9 91
Total operating expenses   16,335 15,817
Operating income (loss)   755 5
Other income (expense)      
Interest   (19) (27)
Other   4 2
Income (loss) before income taxes   740 (20)
Depreciation and amortization included above   397 357
Share-based compensation included in above:      
Capital expenditures   437 254
Life Sciences [Member]      
Revenues:      
Product revenues   7,687 8,002
Royalty and license fee income   400 1,000
Total revenues   8,087 9,002
Operating expenses:      
Cost of product revenues   3,611 3,695
Research and development   667 548
Selling, general and administrative   3,059 3,150
Provision for uncollectible accounts receivable   (4) 11
Legal fee expense   (22) 1
Legal settlement, net   (6,800)  
Total operating expenses   511 7,405
Operating income (loss)   7,576 1,597
Other income (expense)      
Interest   14 2
Other   39 (8)
Foreign exchange gain (loss)   (130) (472)
Income (loss) before income taxes   7,499 1,119
Depreciation and amortization included above   530 560
Share-based compensation included in above:      
Capital expenditures   68 10
Therapeutics [Member]      
Operating expenses:      
Research and development   200 243
Total operating expenses   200 243
Operating income (loss)   (200) (243)
Other income (expense)      
Income (loss) before income taxes   (200) (243)
Depreciation and amortization included above     1
Other Segments [Member]      
Operating expenses:      
Selling, general and administrative   1,880 2,069
Legal fee expense   1,614 2,374
Total operating expenses   3,494 4,443
Operating income (loss)   (3,494) (4,443)
Other income (expense)      
Interest   (35) (44)
Other   11 25
Income (loss) before income taxes   (3,518) (4,462)
Depreciation and amortization included above   23 20
Consolidated [Member]      
Revenues:      
Clinical laboratory services   17,090 15,822
Product revenues   7,687 8,002
Royalty and license fee income   400 1,000
Total revenues   25,177 24,824
Operating expenses:      
Cost of clinical laboratory services   10,332 10,130
Cost of product revenues   3,611 3,695
Research and development   867 791
Selling, general and administrative   10,225 10,285
Provision for uncollectible accounts receivable   704 541
Legal fee expense   1,601 2,466
Legal settlement, net   (6,800)  
Total operating expenses   20,540 27,908
Operating income (loss)   4,637 (3,084)
Other income (expense)      
Interest   (40) (69)
Other   54 19
Foreign exchange gain (loss)   (130) (472)
Income (loss) before income taxes   4,521 (3,606)
Depreciation and amortization included above   950 938
Share-based compensation included in above:      
Capital expenditures   505 264
Cost of Clinical Laboratory Services [Member]      
Share-based compensation included in above:      
Share-based compensation   1 1
Cost of Clinical Laboratory Services [Member] | Clinical Labs [Member]      
Share-based compensation included in above:      
Share-based compensation   1 1
Cost of Clinical Laboratory Services [Member] | Consolidated [Member]      
Share-based compensation included in above:      
Share-based compensation   1 1
Research and Development Expense [Member]      
Share-based compensation included in above:      
Share-based compensation     1
Research and Development Expense [Member] | Life Sciences [Member]      
Share-based compensation included in above:      
Share-based compensation     1
Research and Development Expense [Member] | Consolidated [Member]      
Share-based compensation included in above:      
Share-based compensation     1
Selling, General and Administrative Expenses [Member]      
Share-based compensation included in above:      
Share-based compensation   110 96
Selling, General and Administrative Expenses [Member] | Clinical Labs [Member]      
Share-based compensation included in above:      
Share-based compensation   10 9
Selling, General and Administrative Expenses [Member] | Life Sciences [Member]      
Share-based compensation included in above:      
Share-based compensation   5  
Selling, General and Administrative Expenses [Member] | Other Segments [Member]      
Share-based compensation included in above:      
Share-based compensation   95 87
Selling, General and Administrative Expenses [Member] | Consolidated [Member]      
Share-based compensation included in above:      
Share-based compensation   110 96
Total [Member] | Clinical Labs [Member]      
Share-based compensation included in above:      
Share-based compensation   11 10
Total [Member] | Life Sciences [Member]      
Share-based compensation included in above:      
Share-based compensation   5 1
Total [Member] | Other Segments [Member]      
Share-based compensation included in above:      
Share-based compensation   95 87
Total [Member] | Consolidated [Member]      
Share-based compensation included in above:      
Share-based compensation   $ 111 $ 98